Clinical Trial Update: Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ENaC inhibition to clear mucus in primary ciliary dyskinesia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ciliary Dyskinesia

Drugs mentioned

• ENaC inhibitor (Parion Sciences compound)

Snippet

Sponsor: Parion Sciences | Conditions: Primary Ciliary Dyskinesia | Phase 2 | Status: COMPLETED | Results posted: 2021-12-16